The Priority Review

Policy Brief

Onward Therapeutics closes NT$900 million Series B financing

Onward Therapeutics, Inc. announced it has closed a NT$900 million (approximately US$28 million) Series B financing, its first capital increase in Taiwan since it completed its share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Proceeds will fund the Company's clinical programs, the manufacturing of clinical supplies, and early-stage R&D.

Primary source

Company press release (PR Newswire), November 17, 2026

Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline

Read the source: Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation